Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Nicolas Magné
Based on 10 articles published since 2008
||||

Between 2008 and 2019, N. Magne wrote the following 10 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. 2018

Guillot, B / Charles, J / Jeudy, G / Cupissol, D / Dupuy, A / Dutriaux, C / Gangloff, D / Magne, N / Mirabel, X / M'Sadek, A / Pracht, M / Sichel, C / Do Outeiro, G. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · CHU de Grenoble, 38700 Grenoble, France. · CHU de Dijon, 21000 Dijon, France. · Institut du Cancer de Montpellier, 34298 Montpellier, France. · CHU de Rennes, 35000 Rennes, France. · CHU de Bordeaux, 33000 Bordeaux, France. · Institut universitaire du cancer de Toulouse, 31100 Toulouse, France. · Institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France. · Centre Oscar-Lambret, 59000 Lille, France. · Centre Eugène-Marquis, 35000 Rennes, France. · 13470 Carnoux en Provence, France. · Institut national du cancer de Boulogne-Billancourt, 92100 Boulogne-Billancourt, France. ·Ann Dermatol Venereol · Pubmed #29703640.

ABSTRACT: -- No abstract --

2 Editorial [The frontage and the other headlines]. 2015

Vignot, Stéphane / Magné, Nicolas. ·Hôpital Louis-Pasteur, service d'oncologie et de hématologie, 6, rue Claude-Bernard, 28630 Chartres Le Coudray, France. Electronic address: svignot@ch-chartres.fr. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France. ·Bull Cancer · Pubmed #26281942.

ABSTRACT: -- No abstract --

3 Review [Immunotherapy: Activation of a system not a pathway]. 2017

Bernichon, Emilie / Rancoule, Chloé / Vallard, Alexis / Langrand-Escure, Julien / Mery, Benoîte / Guy, Jean-Baptiste / Magné, Nicolas. ·Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France. · Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France. Electronic address: nicolas.magne@icloire.fr. ·Bull Cancer · Pubmed #28477871.

ABSTRACT: Immunotherapy is on the roll. After revolutionary effects in melanoma, immunotherapy is invading other locations. If current treatments, chemotherapies or targeted therapies block one pathway, immunotherapy should be understood as the activation of a whole system. Indeed, oncogenesis process is defined as an escape of the immune system and the stimulation of this system can block the carcinogenic process. The aim of the present review is to describe the place of immunotherapy in the treatment of solid cancers.

4 Review Melanoma: Last call for radiotherapy. 2017

Espenel, Sophie / Vallard, Alexis / Rancoule, Chloé / Garcia, Max-Adrien / Guy, Jean-Baptiste / Chargari, Cyrus / Deutsch, Eric / Magné, Nicolas. ·Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France. · Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France. Electronic address: chloerancoule@gmail.com. · Public Health Department, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France. · Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France; Department of Radiotherapy, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94800 Villejuif, France. · Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, 108 bis avenue Albert Raimond, BP60008, 42271 Saint Priest en Jarez cedex, France. Electronic address: nicolas.magne@icloire.fr. ·Crit Rev Oncol Hematol · Pubmed #28109401.

ABSTRACT: Melanoma is traditionally considered to be a radioresistant tumor. However, radiotherapy and immunotherapy latest developments might upset this radiobiological dogma. Stereotactic radiotherapy allows high dose per fraction delivery, with high dose rate. More DNA lethal damages, less sublethal damages reparation, endothelial cell apoptosis, and finally clonogenic cell dysfunction are produced, resulting in improved local control. Radiotherapy can also enhance immune responses, inducing neoantigens formation, tumor antigen presentation, and cytokines release. A synergic effect of radiotherapy with immunotherapy is expected, and might lead to abscopal effects. If hadrontherapy biological properties seem able to suppress hypoxia-induced radioresistance and increase biological efficacy, ballistic advantages over photon radiations might also improve radiotherapy outcomes on usually poor prognosis locations. The present review addresses biological and clinical effects of high fraction dose, bystander effect, abscopal effect, and hadrontherapy features in melanoma. Clinical trials results are warranted to establish indications of innovative radiotherapy in melanoma.

5 Review [FGF/FGFR signalling: Implication in oncogenesis and perspectives]. 2015

Flippot, Ronan / Kone, Moumini / Magné, Nicolas / Vignot, Stéphane. ·Gustave-Roussy, département d'innovations thérapeutiques essais précoces, 94800 Villejuif-Grand Paris, France. · Hôpital Louis-Pasteur, service d'oncologie-hématologie, 28630 Chartres-Le-Coudray, France. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France. · Hôpital Louis-Pasteur, service d'oncologie-hématologie, 28630 Chartres-Le-Coudray, France. Electronic address: svignot@ch-chartres.fr. ·Bull Cancer · Pubmed #25986739.

ABSTRACT: Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis. Deregulation of this pathway is reported in various cancers at early stages, and can therefore be responsible for the emergence of the hallmarks of cancer. It is necessary to precise downstream pathways of FGFR signalling to understand its oncogenic potential. We will then describe its implications in different cancer types. Oncogenic mechanisms will be studied through the example of melanoma, in which deregulation of FGF/FGFR pathway is considered as a driver event and occurs in nearly 90% of cases. The FGF/FGFR signalling pathway is a putative therapeutic target. Numerous agents are in active development, operating through a selective or multi-targeted approach. Recent studies have shown rather disappointing results in non-selected patients, but promising results in patients with FGF/FGFR pathway alterations. A careful screening of patients is the key to a valuable evaluation of these new targeted molecular therapies.

6 Review [Primary digestive melanomas: is there any consensus?]. 2014

Eddekkaoui, Houda / Guy, Jean-Baptiste / Falk, Alexander T / Lahmar, Rima / Trone, Jane-Chloé / Bahadoor, Mohun R K / Kullab, Sharif / Collard, Olivier / Rivoirard, Romain / Moriceau, Guillaume / Vignot, Stéphane / Magné, Nicolas. ·Institut de cancérologie Lucien-Neuwirth, Département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France. · Centre Antoine-Lacassagne, Département de radiothérapie, 33, avenue Valombrose, 06100 Nice, France. · Institut de cancérologie Lucien-Neuwirth, Département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France. · Hôpitaux de Chartres, Service d'oncologie et d'hématologie, Site Louis-Pasteur, 28000 Chartres, France. ·Bull Cancer · Pubmed #24977452.

ABSTRACT: In clinical practice and the literature, malignant melanoma usually appears in typical sites where melanocytes can be found: skin, eyes meninges and anal region. Malignant melanomas of the esophagus-gastrointestinal (EGI) tract are usually metastatic. Primary and diffuse EGI tract melanoma is rare and only a few descriptions of this presentation have been found in the literature. The prognosis of EGI tract melanoma is frightening because of late diagnosis and high malignancy potential. Treatment is based essentially on surgery. The objective of the present study is to specify the clinical and therapeutic aspects of primary digestive melanoma.

7 Review [Melanomas of the female genital tract: state of the art]. 2014

Trone, Jane-Chloé / Guy, Jean-Baptiste / Mery, Benoite / Langrand Escure, Julien / Lahmar, Rima / Moncharmont, Coralie / Rivoirard, Romain / Semay, Tiphaine / Chauleur, Céline / Collard, Olivier / Vignot, Stéphane / Magné, Nicolas. ·Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest en Jarez, France. · Département d'oncologie médicale, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest en Jarez, France. · CHU de Saint-Étienne, hôpital Nord, service de gynécologie obstétrique, 42055 Saint-Étienne cedex 2, France. · Groupe hospitalier de la Pitié-Salpêtrière, service d'oncologie médicale, 14, boulevard de l'Hôpital, 75013 Paris, France. ·Bull Cancer · Pubmed #24445910.

ABSTRACT: Melanoma of the female genital tract is a rare location (less than 2% of melanomas all sites combined). These cancers have a very poor prognosis, due to the delay in diagnosis. Vulvar location is about 1% of melanomas then the vaginal location, uterine and ovarian. There is no consensus to date regarding their care, due to the rarity of the lesions. Their treatment must however be based on the current data concerning gynaecological cancers as well as standard management of cutaneous melanoma. The treatment is often based on conservative surgery, because radical resection does not improve survival. For the vulva and vagina, reconstructive surgery is possible. Treatment is sometimes supplemented by chemotherapy or radiotherapy, which could improve local control. The interest in the use of targeted therapy in these locations is not well known because of their rarity, but the study of genes c-Kit and BRAF provides new prospects for treatment. The objective of this review is to describe and report the current state of knowledge about gynaecologic melanomas.

8 Review [Therapeutic strategies and systemic treatment of brain melanoma metastases]. 2013

Durando, Xavier / Mansard, Sandrine / Daste, Amaury / Gimbergues, Pierre / Brocard, Laura / Magné, Nicolas / Thivat, Emilie. ·Centre Jean-Perrin, département d'oncologie, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 1, France. ·Bull Cancer · Pubmed #22889847.

ABSTRACT: Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months. At the moment, there is no standard therapeutic strategy for management of melanoma brain metastases. In some cases, having recourse to a systemic treatment is justified, for example, when brain metastases are combined with a progressive peripheral disease, or with unresecable brain lesions. In France, the use of fotemustine, which received the AMM approval, for metastatic melanoma treatment, is one of the treatments recommended in the case of brain metastases as this chemotherapy, that is active on the melanoma passes the blood-brain barrier. Temozolomide also shows some activity in the brain metastases treatment of melanoma that remains modest in monotherapy but seems interesting when it is combined with radiotherapy. The place of new drugs, in particular ipilimumab and vemurafenib, in the strategy of melanoma brain metastases treatment, still has to be defined and may improve the prognosis of these patients and their quality of life. The new targeted therapies, the widespread use of stereotactic radiosurgery and the improvement in neurosurgical operations would need a prospective clinical assessment, all the more so, in most of clinical studies, the presence of metastases is an exclusion criterion.

9 Article [Role of general practitioners in cancer screening: A survey in the French armed forces]. 2015

Bellier, Thibault / Vallard, Alexis / Espenel, Sophie / Langrand-Escure, Julien / Ben Mrad, Majed / Védrine, Lionel / Magné, Nicolas / Chargari, Cyrus. ·Hôpital d'instruction des armées du Val-de-Grâce, service d'oncologie et de radiothérapie, boulevard du Port-Royal, 75013 Paris, France. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France. · Hôpital d'instruction des armées du Val-de-Grâce, service d'oncologie et de radiothérapie, boulevard du Port-Royal, 75013 Paris, France. Electronic address: chargari-vdg@hotmail.fr. ·Bull Cancer · Pubmed #26628076.

ABSTRACT: INTRODUCTION: The French Military Health Service organizes medical survey of 340,000 military men. The aim of the present study was to evaluate the practices of solid cancer screening of general practitioners in military medical units and to compare the results with the recommendations of the French National Institute of Cancer. METHODS: We conducted a prospective, observational study among general practitioners in Army Medical Unit by sending them a self-assessment questionnaire. Physicians should report on their practices for screening cancers with official screening recommendations. Compliance rates with the recommendations were reviewed. Screening practices for other cancers (prostate cancer, melanoma, thyroid cancer, lung cancer, testicular cancer) were assessed. RESULTS: A total of 133 questionnaires were analyzed. Despite a strong involvement of army general health practitioners, guidelines adherence rates (examination frequency, ages of screening beginning and ending) were of 4% for cervical cancer, 7% for breast cancer, and 37% for colorectal cancer. Those rates are comparable to those reported with civilian general practitioners. For cancers without screening recommendation, practitioners felt highly concerned, especially for the most common cancers among the military population. One third of physicians stated that they had diagnosed a testicular cancer through routine screening. CONCLUSION: Military general health practitioners feel themselves concerned by solid cancer screening, and more particularly for cancers that are the most prevalent in young adults. However, current guidelines are neither known nor applied in routine.

10 Minor Skin cancers in nonagenarian patients: special focus on radiotherapy. 2015

Trone, J-C / Mengue Ndong, S / Falk, A T / Annede, P / Rivoirard, R / Guy, J-B / Langrand-Escure, J / Méry, B / Espenel, S / Ben Mrad, M / Vallard, A / Auberdiac, P / Moncharmont, C / Assouline, A / de Laroche, G / Chargari, C / Magné, N. ·Radiation Oncology, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France. · Radiation Oncology, Centre Antoine Lacassagne, Nice, France. · Medical and Radiation Oncology, Hôpital d'Instruction des Armées du Val-de-Grâce, France. · Radiation Oncology, Clinique Claude Bernard, Albi, France. · Radiation Oncology, Centre Clinique de la Porte de Saint Cloud, Boulogne-Billancourt, France. ·Clin Oncol (R Coll Radiol) · Pubmed #25681870.

ABSTRACT: -- No abstract --